At NS Pharma, leadership is more than just a role—it’s a commitment to empowering teams, fostering innovation, and building strong partnerships that push the boundaries of rare disease treatments.
The newest member of our executive team, Don Foy, embodies this approach. With over 24 years of pharma experience—including 17 in leadership roles—Don brings a wealth of expertise in sales, marketing, market access, and commercial strategy to his role as head of Commercial. This expertise is grounded in a leadership style that prioritizes trust, collaboration, and professional development.
Don Foy, Head of Commercial, NS Pharma
Trust as the Cornerstone of Leadership
Shinrai is the Japanese word for trust, a core value that shapes every aspect of our work at NS Pharma. For Don, building trust through integrity is not just a professional value but a personal one, rooted in lessons he learned from his father.
He remembers how his father, an association executive, led with empathy, care, and a deep commitment to his team’s well-being: “I observed how he treated and led people, and when he retired, the accolades that he received from his staff were quite overwhelming,” Don recalls.
This early lesson has shaped Don’s belief that great leadership comes from genuinely caring for those you lead: “Trust is the foundation for everything, be it internal or external relationships,” he explains. “As a leader, you have to demonstrate care and concern for the people you serve. They also need to see your vulnerabilities. The more you can do that, the more you connect and build trust with your people.”
For Don and the rest of NS Pharma’s executive team, trust built on transparency and integrity is the critical element that fosters collaboration, enhances performance, and creates lasting partnerships. Shinrai isn’t just an internal value at NS Pharma—it shapes our relationships with healthcare professionals, industry partners, and the patients we serve.
[Don with his father]
Collaboration accelerates drug development. At NS Pharma, the Commercial team is pivotal in maintaining strategic partnerships that allow us to bring life-changing therapies to patients with rare diseases.
A prime example is our ongoing collaboration with Capricor Therapeutics to launch deramiocel (CAP-1002), a new cell therapy product for Duchenne muscular dystrophy. Don’s team ensures seamless execution at every step of the partnership—from planning to launch. This starts with aligning internal and external stakeholders through open communication and mutual accountability.
According to Don, successful partnerships hinge on three fundamental principles:
This hands-on approach enables NS Pharma’s Commercial team to be proactive, adapt swiftly to meet challenges, and ensure complete alignment—keeping the focus on delivering safe and effective therapies to patients as quickly as possible.
Our extensive commercial infrastructure is one of our greatest strengths, providing an invaluable advantage to our partners. With cross-continental reach and a finely tuned distribution network, we deliver an efficient, scalable platform to drive sales and maximize market reach.
The Commercial team supports this infrastructure, with senior directors overseeing patient services, market access, sales, marketing, and operations. “Our senior directors coordinate with consultants, healthcare professionals, patients, payers, advocacy organizations, and other groups, keeping us aligned to ensure we successfully accomplish our commercial objectives,” Don explains.
Through NS Pharma’s strategic leadership, cross-departmental coordination, and robust international sales infrastructure, our partners can confidently focus on innovation, knowing they have a dependable partner for commercialization success.
>Partner with us to advance rare disease treatment<
Shaping the Future Together
Under Don’s leadership, the Commercial team continues to build strong partnerships, empower future leaders, and drive the development of groundbreaking therapies that make a real difference in the lives of patients with rare diseases. “To be able to manage Viltepso, a four-year-old product in the marketplace, and the opportunity to launch an exciting new product in cell therapy,” remarks Don. “What an exciting time to be at NS Pharma.”
We couldn’t agree more. Whether you’re looking to partner with NS Pharma or join our growing team, we invite you to be part of the exciting breakthroughs shaping the future of rare disease treatment. Together, guided by the principles of Shinrai and a shared commitment to improving patient outcomes, we’re building a future that brings hope and healing to those who need it most.
Transform the future of rare disease treatment with us.
